

**26-MAY-2017 18:10  
CANCER CONTROL ACCRUAL REPORT**

STUDY	O R P E E G N	ARM	TOTAL	REGS.	REGS.	REGS.	REGS.	REGS.	ADMIN			
			REGS.	LAST Month	LAST Month	LAST Month	LAST Month	LAST Month		LAST Month		
S1007-Breast,Adj,N1,Endocrine+/-Chemo	1	Y 1	Recurrence Score testing	9138	812	403	219	82	19	BREAST		
				9138	812	403	219	82	19			
	2	Y 2	Chemo and Endocrine Therapy	2452	274	125	73	27	4			
				3	Endocrine Therapy Alone	2443	275	131	78		28	7
						4895	549	256	151		55	11
S1207-Brst,Adj,Endocrine+/-Everolimus	1	Y 1	Blinded drug + Endocrine	618	227	115	63	18	5	BREAST		
			2	Blinded drug + Endocrine	612	222	110	60	19		4	
			1230	449	225	123	37	9				
S1316-Compar. Effectiv. Trial for MBO	1	Y 1	Randomization: Surgery	1	0	0	0	0	0	SURV		
			3	Patient Choice: Surgery	25	17	9	5	2		0	
			4	Patient Choice: Non-surgical M	53	33	19	10	2		0	
			79	50	28	15	4	0				
S1404-Melan, Adv, HD-IFN/Ipilimumab vs MK-3475	1	Y 1	Tissue for PD-L1 testing	1150	980	545	279	92	20	MELAN		
				1150	980	545	279	92	20			
	2	Y 2	FDA approved regimen	525	460	268	130	38	15			
				3	MK-3475 (Pembrolizumab)	518	454	254	132		39	8
						1043	914	522	262		77	23
S1415CD-TrACER CSF Standing Order Intervention for FN	1	Y 1	Site assigned to Cohort	205	205	193	114	38	10	CCD		
			2	Site randomized: Control	75	75	75	64	20		5	
			3	SiteRand Int Risk: CSF	102	102	102	62	23		6	
			4	SiteRand Int Risk: No CSF	66	66	65	50	29		7	
			448	448	435	290	110	28				
S1417CD-Colorectal, Cost Cohort Study	1	Y 1	Observation	55	55	44	31	14	4	CCD		
				55	55	44	31	14	4			
S1418-Breast, Adj, TNBC, MK-3475 (Pembrolizumab)	1	Y 1	Tissue for PD-L1 testing	32	32	32	26	14	4	BREAST		
				32	32	32	26	14	4			
	2	Y 2	Observation	11	11	11	11	7	4			
				3	MK-3475 (Pembrolizumab)	13	13	13	10		7	2
						24	24	24	21		14	6

**26-MAY-2017 18:10  
CANCER CONTROL ACCRUAL REPORT**

STUDY	O R P E E G N	ARM	TOTAL	REGS.	REGS.	REGS.	REGS.	REGS.	ADMIN	
			REGS.	LAST 12 Month	LAST 6 Month	LAST 3 Month	LAST 30 DAYS	LAST 7 DAYS		
S1602-Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG	1	Y 1	TICE BCG	4	4	4	4	1	0	GU
			2 Tokyo-172 BCG	2	2	2	2	0	0	
			3 Prime + Tokyo-172 BCG	3	3	3	3	2	1	
				9	9	9	9	3	1	
S0820-PACES: ColrecStg0-3 Blind DFMO/Sulindac	0	Y 0	Pre-Registration	353	124	64	26	11	0	PREV
				353	124	64	26	11	0	
	1	Y 1	Blinded drug	39	18	9	7	3	0	
			2 Blinded drug	36	12	9	2	0	0	
			3 Blinded drug	35	14	9	3	0	0	
			4 Blinded drug	37	14	10	7	2	0	
			147	58	37	19	5	0		